Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID06752668

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Led by Centessa Pharmaceuticals (UK) Limited · Updated on 2026-04-27

248

Participants Needed

37

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH). These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups: those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.

CONDITIONS

Brief Title

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 65 years
  • Body mass index (BMI) between 17 and 37 kg/m2
  • Diagnosed with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia by ICSD-3-TR criteria
  • Willing and able to stop all medications for narcolepsy or idiopathic hypersomnia
  • Willing and able to follow all study requirements
Not Eligible

You will not qualify if you...

  • Having any medical disorder other than NT1, NT2, or IH that causes excessive daytime sleepiness
  • Having significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, cancer, endocrine, neurological, or psychiatric disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Up to 28 days

Participants receive ORX750 or placebo capsules to assess safety, tolerability, and effects on narcolepsy and idiopathic hypersomnia.

Visits on Day 1, 15, and 28

Trial Site Locations

Total: 37 locations

1

Auburn, Alabama

Auburn, Alabama, United States, 36832

Actively Recruiting

2

Chandler, Arizona

Chandler, Arizona, United States, 85224

Actively Recruiting

3

Scottsdale, Arizona

Scottsdale, Arizona, United States, 85253

Actively Recruiting

4

Long Beach, California

Long Beach, California, United States, 90805

Actively Recruiting

5

Santa Ana, California

Santa Ana, California, United States, 92705

Actively Recruiting

6

Brandon, Florida

Brandon, Florida, United States, 33511

Actively Recruiting

7

Miami, Florida

Miami, Florida, United States, 33155

Actively Recruiting

8

Miami, Florida

Miami, Florida, United States, 33176

Actively Recruiting

9

Orlando, FL

Orlando, Florida, United States, 32807

Actively Recruiting

10

Winter Park, Florida

Winter Park, Florida, United States, 32789

Actively Recruiting

11

Atlanta, Georgia

Atlanta, Georgia, United States, 30281

Actively Recruiting

12

Atlanta, Georgia

Atlanta, Georgia, United States, 30328

Actively Recruiting

13

Riverdale, Georgia

Riverdale, Georgia, United States, 30274

Actively Recruiting

14

New Orleans, Louisiana

New Orleans, Louisiana, United States, 70127

Actively Recruiting

15

Newton, Massachusetts

Newton, Massachusetts, United States, 02459

Actively Recruiting

16

Southfield, Michigan

Southfield, Michigan, United States, 48075

Actively Recruiting

17

Sterling Heights, Michigan

Sterling Heights, Michigan, United States, 48314

Actively Recruiting

18

Henderson, Nevada

Henderson, Nevada, United States, 89052

Actively Recruiting

19

Denver, North Carolina

Denver, North Carolina, United States, 28037

Actively Recruiting

20

Huntersville, North Carolina

Huntersville, North Carolina, United States, 28078

Actively Recruiting

21

Cincinnati, Ohio

Cincinnati, Ohio, United States, 45245

Actively Recruiting

22

Cleveland, OH

Cleveland, Ohio, United States, 44106

Actively Recruiting

23

Dublin, Ohio

Dublin, Ohio, United States, 43017

Actively Recruiting

24

Willow Grove, Pennsylvania

Willow Grove, Pennsylvania, United States, 19090

Actively Recruiting

25

Columbia, South Carolina

Columbia, South Carolina, United States, 29201

Actively Recruiting

26

North Charleston, South Carolina

North Charleston, South Carolina, United States, 29406

Actively Recruiting

27

Austin, Texas

Austin, Texas, United States, 78731

Actively Recruiting

28

El Paso, TX

El Paso, Texas, United States, 79912

Actively Recruiting

29

San Antonio, Texas

San Antonio, Texas, United States, 78229

Actively Recruiting

30

Toronto, Ontario

Toronto, Ontario, Canada, M5S 3A3

Actively Recruiting

31

Leon, France

Léon, Bordeaux, France, 33000

Actively Recruiting

32

Bologna, Italy

Bologna, Italy, 40139

Actively Recruiting

33

Pozzilli, Italy

Pozzilli, Italy, 86077

Actively Recruiting

34

Verona, Italy

Verona, Italy, 37134

Actively Recruiting

35

Madrid, Spain

Madrid, Spain, 28036

Actively Recruiting

36

Madrid, Spain

Madrid, Spain, 28043

Actively Recruiting

37

Vitoria-Gasteiz, Spain

Vitoria-Gasteiz, Spain, 01009

Actively Recruiting

Loading map...

Research Team

C

Centessa Pharmaceuticals

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Similar Trials

A Chronobiological Treatment Combining Evening Melatonin and...

Idiopathic Hypersomnia

Actively Recruiting

1 location

A Phase 2 Long-term Extension Study of the Safety and Effica...

Narcolepsy Type 1

Actively Recruiting

24 locations

An Open-Label, Long-Term Extension Study to Investigate the ...

Narcolepsy Type 1

Actively Recruiting

46 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here